Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk

NCT02394769 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02394769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02394769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk
Lead sponsor
Massachusetts General Hospital
Phase
Not applicable
Overall status
Active, not recruiting
Start date
July 6, 2015
Completion date
July 31, 2029
Enrollment
180 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer